Prognostic Value of CYFRA 21 - 1 and Ki67 in Advanced NSCLC Patients with Wild-type EGFR

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Apr 2

PMID 37004004

Authors

Tao Li

Qi Xie

Yang-Yang Fang

Yi Sun

Xiao Ming Wang

Zhu Luo

Gui-Ling Yan

Jian-Bo He

Xiao-Qun Zheng

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic value of cytokeratin 19 fragment (CYFRA 21 - 1) and Ki67 in advanced non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) remains to be explored.

Methods: In this study, 983 primary NSCLC patients from January 2016 to December 2019 were retrospectively reviewed. Finally, 117 advanced NSCLC patients with wild-type EGFR and 37 patients with EGFR mutation were included and prognostic value of CYFRA 21 - 1 and Ki67 were also identified.

Results: The patients age, smoking history and the Eastern Corporative Oncology Group (ECOG) performance scores were significantly different between CYFRA21-1 positive and negative groups (p < 0.05), while no significant differences were found in Ki67 high and low groups. The results of over survival (OS) demonstrated that patients with CYFRA21-1 positive had markedly shorter survival time than CYFRA21-1 negative (p < 0.001, For whole cohorts; p = 0.002, For wild-type EGFR). Besides, patients with wild-type EGFR also had shorter survival times than Ki67 high group. Moreover, In CYFRA 21 - 1 positive group, patients with Ki67 high had obviously shorter survival time compared to patients with Ki67 low (median: 24vs23.5 months; p = 0.048). However, Ki67 could not be used as an adverse risk factor for patients with EGFR mutation. Multivariate cox analysis showed that age (HR, 1.031; 95%CI, 1.003 ~ 1.006; p = 0.028), Histopathology (HR, 1.760; 95%CI,1.152 ~ 2.690; p = 0.009), CYFRA 21 - 1 (HR, 2.304; 95%CI,1.224 ~ 4.335; p = 0.01) and Ki67 (HR, 2.130; 95%CI,1.242 ~ 3.652; p = 0.006) served as independent prognostic risk factor for advanced NSCLC patients.

Conclusions: Our finding indicated that CYFRA 21 - 1 was an independent prognostic factor for advanced NSCLC patients and Ki67 status could be a risk stratification marker for CYFRA 21 - 1 positive NSCLC patients with wild-type EGFR.

Citing Articles

A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers.

Pan X, Wei C, Su J, Fang M, Lin Q, Qin Y Front Immunol. 2025; 16:1531708.

PMID: 40070823 PMC: 11894575. DOI: 10.3389/fimmu.2025.1531708.

References

Yan S, Shun-Chang J, Li C, Jie L, Ya-Li L, Ling-Xiong W . Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer. 2010; 10:621. PMC: 2988758. DOI: 10.1186/1471-2407-10-621. View

Sheard M, Vojtesek B, Simickova M, Valik D . Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem. 2002; 85(4):670-7. DOI: 10.1002/jcb.10173. View

Kremer R, Best L, Savulescu D, Gavish M, Nagler R . Pleural fluid analysis of lung cancer vs benign inflammatory disease patients. Br J Cancer. 2010; 102(7):1180-4. PMC: 2853096. DOI: 10.1038/sj.bjc.6605607. View

Peng H, Tan X, Wang Y, Dai L, Liang G, Guo J . Clinical significance of Ki67 and circulating tumor cells with an epithelial-mesenchymal transition phenotype in non-small cell lung cancer. Am J Transl Res. 2020; 12(6):2916-2928. PMC: 7344100. View

Scagliotti G, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P . Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer. 1993; 29A(3):363-5. DOI: 10.1016/0959-8049(93)90387-u. View

Rusch V, Chansky K, Kindler H, Nowak A, Pass H, Rice D . The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016; 11(12):2112-2119. DOI: 10.1016/j.jtho.2016.09.124. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Chilosi M, Murer B . Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med. 2010; 134(1):55-65. DOI: 10.5858/134.1.55. View

Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R . Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer. 2015; 87(2):193-200. DOI: 10.1016/j.lungcan.2014.12.006. View

10.

Li J, Yang F, Li X, Zhang M, Fu R, Yin X . Characteristics, survival, and risk factors of Chinese young lung cancer patients: the experience from two institutions. Oncotarget. 2017; 8(51):89236-89244. PMC: 5687685. DOI: 10.18632/oncotarget.19183. View

11.

Ciancio N, Galasso M, Campisi R, Bivona L, Migliore M, Di Maria G . Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med. 2012; 7(1):29. PMC: 3537558. DOI: 10.1186/2049-6958-7-29. View

12.

Yu Z, Zhang G, Yang M, Zhang S, Zhao B, Shen G . Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis. Oncotarget. 2016; 8(3):4043-4050. PMC: 5354811. DOI: 10.18632/oncotarget.14022. View

13.

Bozzetti C, Franciosi V, Crafa P, Carbognani P, Rusca M, Nizzoli R . Biological variables in non-small cell lung cancer: comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections. Lung Cancer. 2000; 29(1):33-41. DOI: 10.1016/s0169-5002(00)00095-7. View

14.

Siegfried J, Gubish C, Rothstein M, Henry C, Stabile L . Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2012; 7(3):485-95. PMC: 3288546. DOI: 10.1097/JTO.0b013e31824177ea. View

15.

Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M . Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res. 2000; 19(4C):3613-8. View

16.

Cai Z . Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients. Onco Targets Ther. 2016; 9:3873-8. PMC: 4930226. DOI: 10.2147/OTT.S102199. View

17.

DallOlio F, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N . Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 19(2):75-90. DOI: 10.1038/s41571-021-00564-3. View

18.

Molina R, Marrades R, Auge J, Escudero J, Vinolas N, Reguart N . Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. Am J Respir Crit Care Med. 2015; 193(4):427-37. DOI: 10.1164/rccm.201404-0603OC. View

19.

Wang S, Ma P, Ma G, Lv Z, Wu F, Guo M . Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis. Eur J Cancer. 2019; 124:1-14. DOI: 10.1016/j.ejca.2019.10.005. View

20.

Yoshimura A, Uchino J, Hasegawa K, Tsuji T, Shiotsu S, Yuba T . Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2019; 8(3):227-234. PMC: 6626854. DOI: 10.21037/tlcr.2019.06.08. View